Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize β-adrenergic receptor function in heart failure

Vascular Pharmacology

Volumn 45, Issue 2, 2006, Pages 77-85

  Perrino, Cinzia ^a   Rockman, Howard A ^b   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adrenergic receptor; Human heart failure; Phosphorylation

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR KINASE 1; ISOPRENALINE; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CYTOSOL; DETERIORATION; DISEASE COURSE; ENDOCYTOSIS; ENZYME INHIBITION; HEART FAILURE; HEART HYPERTROPHY; HEART PERFORMANCE; HEART STRESS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SURVIVAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADRENERGIC BETA-AGONISTS; DOWN-REGULATION; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; MULTIPROTEIN COMPLEXES; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, ADRENERGIC, BETA-1; SIGNAL TRANSDUCTION;

EID: 33748538992     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.01.018     Document Type: Article

References (53)

1. Akhter S.A., Luttrell L.M., Rockman H.A., Iaccarino G., Lefkowitz R.J., and Koch W.J. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280 (1998) 574-577
2. Alloatti G., Levi R., Malan D., et al. Phosphoinositide 3-kinase gamma-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. Cardiovasc. Res. 60 (2003) 242-249
3. Bisognano J.D., Weinberger H.D., Bohlmeyer T.J., et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J. Mol. Cell. Cardiol. 32 (2000) 817-830
4. Bristow M.R. Why does the myocardium fail? Insights from basic science. Lancet 352 Suppl. 1 (1998) SI8-SI14
5. Bristow M.R., Ginsburg R., Minobe W., et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. 307 (1982) 205-211
6. Bristow M.R., Minobe W.A., Raynolds M.V., et al. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J. Clin. Invest. 92 (1993) 2737-2745
7. Crackower M.A., Oudit G.Y., Kozieradzki I., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110 (2002) 737-749
8. DeFea K.A., Zalevsky J., Thoma M.S., Dery O., Mullins R.D., and Bunnett N.W. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J. Cell Biol. 148 (2000) 1267-1281
9. Dhand R., Hiles I., Panayotou G., et al. PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J. 13 (1994) 522-533
10. Engelhardt S., Hein L., Wiesmann F., and Lohse M.J. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7059-7064
11. Esposito G., Rapacciuolo A., Naga Prasad S.V., et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105 (2002) 85-92
12. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53 (2001) 1-24
13. Gaidarov I., and Keen J.H. Phosphoinositide-AP-2 interactions required for targeting to plasma membrane clathrin-coated pits. J. Cell Biol. 146 (1999) 755-764
14. Gaidarov I., Krupnick J.G., Falck J.R., Benovic J.L., and Keen J.H. Arrestin function in G protein-coupled receptor endocytosis requires phosphoinositide binding. EMBO J. 18 (1999) 871-881
15. Harding V.B., Jones L.R., Lefkowitz R.J., Koch W.J., and Rockman H.A. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5809-5814
16. Hirsch E., Katanaev V.L., Garlanda C., et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287 (2000) 1049-1053
17. Hu P., Mondino A., Skolnik E.Y., and Schlessinger J. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol. Cell. Biol. 13 (1993) 7677-7688
18. Iaccarino G., Tomhave E.D., Lefkowitz R.J., and Koch W.J. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 98 (1998) 1783-1789
19. Iaccarino G., Lefkowitz R.J., and Koch W.J. Myocardial G protein-coupled receptor kinases: implications for heart failure therapy. Proc. Assoc. Am. Physicians 111 (1999) 399-405
20. Inglese J., Freedman N.J., Koch W.J., and Lefkowitz R.J. Structure and mechanism of the G protein-coupled receptor kinases. J. Biol. Chem. 268 (1993) 23735-23738
21. Iwase M., Bishop S.P., Uechi M., et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. Circ. Res. 78 (1996) 517-524
22. 2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin. J. Clin. Invest. 101 (1998) 1385-1393
23. Koch W.J., Rockman H.A., Samama P., et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 268 (1995) 1350-1353
24. Krueger K.M., Daaka Y., Pitcher J.A., and Lefkowitz R.J. The role of sequestration in G protein-coupled receptor resensitization. Regulation of beta2-adrenergic receptor dephosphorylation by vesicular acidification. J. Biol. Chem. 272 (1997) 5-8
25. Laporte S.A., Oakley R.H., Holt J.A., Barak L.S., and Caron M.G. The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits. J. Biol. Chem. 275 (2000) 23120-23126
26. Lefkowitz R.J., and Whalen E.J. Beta-arrestins: traffic cops of cell signaling. Curr. Opin. Cell Biol. 16 (2004) 162-168
27. Luttrell L.M., Ferguson S.S., Daaka Y., et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283 (1999) 655-661
28. McMullen J.R., Shioi T., Zhang L., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12355-12360
29. Naga Prasad S.V., Esposito G., Mao L., Koch W.J., and Rockman H.A. Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J. Biol. Chem. 275 (2000) 4693-4698
30. Naga Prasad S.V., Barak L.S., Rapacciuolo A., Caron M.G., and Rockman H.A. Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase: 1. A role in receptor sequestration. J. Biol. Chem. 276 (2001) 18953-18959
31. Naga Prasad S.V., Laporte S.A., Chamberlain D., Caron M.G., Barak L., and Rockman H.A. Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J. Cell Biol. 158 (2002) 563-575
32. Naga Prasad S.V., Jayatilleke A., Madamanchi A., and Rockman H.A. Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. Nat. Cell. Biol. 8 (2005) 785-796
33. Nienaber J.J., Tachibana H., Naga Prasad S.V., et al. Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J. Clin. Invest. 112 (2003) 1067-1079
34. Odley A., Hahn H.S., Lynch R.A., et al. Regulation of cardiac contractility by Rab4-modulated beta2-adrenergic receptor recycling. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 7082-7087
35. Patrucco E., Notte A., Barberis L., et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118 (2004) 375-387
36. Perrino C., Naga Prasad S.V., Schroder J.N., Hata J.A., Milano C., and Rockman H.A. Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex. Circulation 111 (2005) 2579-2587
37. Perrino C., Naga Prasad S.V., Patel M., Wolf M.J., and Rockman H.A. Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J. Am. Coll. Cardiol. 45 (2005) 1862-1870
38. Perrino C., Prasad S.V., Mao L., Noma T., Yan Z., Kim H.S., Smithies O., and Rockman H.A. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J. Clin. Invest. 116 6 (2006) 1547-1560 (Jun)
39. Perry S.J., and Lefkowitz R.J. Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol. 12 (2002) 130-138
40. Petrofski J.A., and Koch W.J. The beta-adrenergic receptor kinase in heart failure. J. Mol. Cell. Cardiol. 35 (2003) 1167-1174
41. Pierce K.L., Luttrell L.M., and Lefkowitz R.J. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20 (2001) 1532-1539
42. Ping P., Gelzer-Bell R., Roth D.A., Kiel D., Insel P.A., and Hammond H.K. Reduced betaadrenergic receptor activation decreases G-protein expression and beta-adrenergic receptor kinase activity in porcine heart. J. Clin. Invest. 95 (1995) 1271-1280
43. Rapacciuolo A., Esposito G., Caron K., Mao L., Thomas S.A., and Rockman H.A. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J. Am. Coll. Cardiol. 38 (2001) 876-882
44. Remme W.J. Inodilator therapy for heart failure. Early, late, or not at all?. Circulation 87 (1993) IV97-IV107
45. Rockman H.A., Ross R.S., Harris A.N., et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 8277-8281
46. Rockman H.A., Chien K.R., Choi D.J., et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7000-7005
47. Rockman H.A., Koch W.J., and Lefkowitz R.J. Seven-transmembrane-spanning receptors and heart function. Nature 415 (2002) 206-212
48. Shioi T., Kang P.M., Douglas P.S., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19 (2000) 2537-2548
49. Stoyanov B., Volinia S., Hanck T., et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269 (1995) 690-693
50. Thomas S.A., Matsumoto A.M., and Palmiter R.D. Noradrenaline is essential for mouse fetal development. Nature 374 (1995) 643-646
51. Ungerer M., Bohm M., Elce J.S., Erdmann E., and Lohse M.J. Altered expression of betaadrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 87 (1993) 454-463
52. Vanhaesebroeck B., Leevers S.J., Ahmadi K., et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70 (2001) 535-602
53. White D.C., Hata J.A., Shah A.S., Glower D.D., Lefkowitz R.J., and Koch W.J. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5428-5433